Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells

Clinical and Experimental Medicine

Volumn 13, Issue 1, 2013, Pages 75-80

  Pezuk, Julia A ^a   Brassesco, María Sol ^a   Oliveira, Jaqueline C ^a   Morales, Andressa G ^a   Montaldi, Ana P ^a   Sakamoto Hojo, Elza T ^a   Scrideli, Carlos A ^a   Tone, Luiz G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apoptosis; BI 2536; Cervical carcinoma; Mitotic arrest

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CASPASE 3; POLO LIKE KINASE 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INDEX; PRIORITY JOURNAL; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CARCINOMA;

EID: 84873715461     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-011-0166-1     Document Type: Article

References (12)

1. Sahdev A (2010) Cervical tumors. Semin Ultrasound CT MR 31:399-413
2. Winkles JA, Alberts GF (2005) Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24:260-266
3. Saxena M, Singh S, Negi MP, Srivastava AK, Trivedi R, Singh U, Pant MC, Bhatt ML (2010) Expression profiling of G2/M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients. J Cancer Res Ther 6:167-171
4. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94:1863-1877
5. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ (2007) BI 2536 a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316-322
6. Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N (2009) Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 129:2843-2853
7. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK (1997) Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 234:397-405
8. Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, de Boer RA, Silljé HH (2010) The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PLoS One 5:e12963
9. Gao Q, Huang X, Tang D, Cao Y, Chen G, Lu Y, Zhuang L, Wang S, Xu G, Zhou J, Ma D (2006) Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Apoptosis 11:1789-1800
10. Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, Zeuzem S (2003) Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 22:69-80
11. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM (2007) The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 17:304-315
12. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26:5511-5517